These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 12019167)
1. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Sun Y; Sijts AJ; Song M; Janek K; Nussbaum AK; Kral S; Schirle M; Stevanovic S; Paschen A; Schild H; Kloetzel PM; Schadendorf D Cancer Res; 2002 May; 62(10):2875-82. PubMed ID: 12019167 [TBL] [Abstract][Full Text] [Related]
2. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Parkhurst MR; Fitzgerald EB; Southwood S; Sette A; Rosenberg SA; Kawakami Y Cancer Res; 1998 Nov; 58(21):4895-901. PubMed ID: 9809996 [TBL] [Abstract][Full Text] [Related]
3. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation. Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990 [TBL] [Abstract][Full Text] [Related]
4. Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. van Hall T ; Sijts A; Camps M; Offringa R; Melief C; Kloetzel PM; Ossendorp F J Exp Med; 2000 Aug; 192(4):483-94. PubMed ID: 10952718 [TBL] [Abstract][Full Text] [Related]
5. A role for the proteasome regulator PA28alpha in antigen presentation. Groettrup M; Soza A; Eggers M; Kuehn L; Dick TP; Schild H; Rammensee HG; Koszinowski UH; Kloetzel PM Nature; 1996 May; 381(6578):166-8. PubMed ID: 8610016 [TBL] [Abstract][Full Text] [Related]
6. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Strehl B; Seifert U; Krüger E; Heink S; Kuckelkorn U; Kloetzel PM Immunol Rev; 2005 Oct; 207():19-30. PubMed ID: 16181324 [TBL] [Abstract][Full Text] [Related]
7. PI31 is a modulator of proteasome formation and antigen processing. Zaiss DM; Standera S; Kloetzel PM; Sijts AJ Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14344-9. PubMed ID: 12374861 [TBL] [Abstract][Full Text] [Related]
8. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Carrabba MG; Castelli C; Maeurer MJ; Squarcina P; Cova A; Pilla L; Renkvist N; Parmiani G; Rivoltini L Cancer Res; 2003 Apr; 63(7):1560-7. PubMed ID: 12670905 [TBL] [Abstract][Full Text] [Related]
9. Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Sun Y; Song M; Stevanović S; Jankowiak C; Paschen A; Rammensee HG; Schadendorf D Int J Cancer; 2000 Aug; 87(3):399-404. PubMed ID: 10897046 [TBL] [Abstract][Full Text] [Related]
10. Molecular cloning of proteasome activator PA28-beta subunit of large yellow croaker (Pseudosciana crocea) and its coordinated up-regulation with MHC class I alpha-chain and beta 2-microglobulin in poly I:C-treated fish. Liu G; Zheng W; Chen X Mol Immunol; 2007 Feb; 44(6):1190-7. PubMed ID: 16901544 [TBL] [Abstract][Full Text] [Related]
11. The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation. Textoris-Taube K; Henklein P; Pollmann S; Bergann T; Weisshoff H; Seifert U; Drung I; Mügge C; Sijts A; Kloetzel PM; Kuckelkorn U J Biol Chem; 2007 Apr; 282(17):12749-54. PubMed ID: 17308306 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. Schwarz K; van Den Broek M; Kostka S; Kraft R; Soza A; Schmidtke G; Kloetzel PM; Groettrup M J Immunol; 2000 Jul; 165(2):768-78. PubMed ID: 10878350 [TBL] [Abstract][Full Text] [Related]
14. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Dupont J; Latouche JB; Ma C; Sadelain M Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591 [TBL] [Abstract][Full Text] [Related]
15. Antigen presentation of a modified tumor-derived peptide by tumor infiltrating lymphocytes. Dionne SO; Smith MH; Marincola FM; Lake DF Cell Immunol; 2001 Dec; 214(2):139-44. PubMed ID: 12088412 [TBL] [Abstract][Full Text] [Related]
16. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient. Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215 [TBL] [Abstract][Full Text] [Related]
17. The effect of the interferon-gamma-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context. Kuckelkorn U; Ferreira EA; Drung I; Liewer U; Kloetzel PM; Theobald M Eur J Immunol; 2002 May; 32(5):1368-75. PubMed ID: 11981824 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells. Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094 [TBL] [Abstract][Full Text] [Related]
19. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Murray JL; Gillogly M; Kawano K; Efferson CL; Lee JE; Ross M; Wang X; Ferrone S; Ioannides CG Cancer Res; 2004 Aug; 64(15):5481-8. PubMed ID: 15289358 [TBL] [Abstract][Full Text] [Related]
20. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]